[Dalargin--a peptide preparation with cytoprotective action].
The role and possible clinical use of regulatory peptides, a new type of regulatory substances, is discussed. Special attention is paid to the opioid peptides and their analogues. The new drug dalargin has been developed on the basis of the endogenous opioid peptide leucine-encephalin. Its action has been studied using experimental models. It has been established that the optimal dose (10 micrograms/kg) of dalargin is effective in preventing ulceration in the cystamine duodenal ulcer rat model and the development of stomach erosive lesions in immobilization stress, reducing the degree of liver degeneration in CCl4 poisoning, etc. With an increase of the dose of dalargin the effect "escapes". Dalargin is primarily bound by delta-receptors, it produces no analgetic effect and does not enter the brain. Dalargin exhibits a pronounced cytoprotective and regeneratory action and may take an important place in treating the internal organ diseases.
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D051379:Mice; D009336:Necrosis; D010179:Pancreas / Q000473:pathology; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects; D013276:Stomach Ulcer / Q000188:drug therapy / Q000209:etiology
D011957:Receptors, Opioid; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Dalargin--a peptidnyĭ preparat s tsitoprotektivnym deĭstviem.